Business, energy, technology, markets and global industry news from Business News Today

Pharma.AI

PharmaDeviceNews Pharma.AI
Insilico Medicine and Bora Pharmaceuticals plan a proposed US$2.5 billion alliance linking AI-driven drug discovery with pharmaceutical development and manufacturing. Representative image.
Pharma & Biotech

A US$2.5bn AI drug alliance is taking shape, but what have Insilico and Bora actually agreed?

Insilico Medicine and Bora Pharmaceuticals propose an AI drug alliance worth over US$2.5 billion, but definitive agreements remain pending.

Read More
Pharma & Biotech

Insilico Medicine’s AI-originated IPF drug enters Phase 3, but the hardest test begins now

Find out how Insilico Medicine’s AI-originated rentosertib is entering Phase 3 testing for idiopathic pulmonary fibrosis.

Read More
Representative image: AI-driven pharmaceutical research combining advanced molecular modelling, laboratory automation and drug discovery workflows, reflecting the strategic collaboration between Insilico Medicine and Takeda Pharmaceutical Company.
Pharma & Biotech

Insilico Medicine secures Takeda collaboration to advance AI-designed drug candidates

Discover how Takeda’s $600 million Insilico Medicine collaboration could reshape AI drug discovery, candidate design and clinical translation.

Read More
Representative image: AI-powered drug discovery research lab illustrating Insilico Medicine and SK Biopharmaceuticals’ $2.5 billion CNS neuroimmune drug development pact.
Pharma & Biotech

Why Insilico’s $2.5bn SK Biopharmaceuticals deal could reshape AI drug discovery

Find out how Insilico and SK Biopharmaceuticals are using AI to target neuroimmune CNS disorders in a $2.5B drug discovery pact.

Read More